Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.APHB · Entity 6329 | Director | September 07, 2017 | September 12, 2017 |
| EXAGEN INC.XGN · Entity 935 | Director | June 09, 2023 | June 13, 2023 |
| OnKure Therapeutics, Inc.RPHM · Entity 6550 | Chief Development Officer | July 14, 2021 | July 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date September 07, 2017 · Filed September 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2027-09-06 | Direct | 10,900 |
Reported balance
After 2017-09-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-09-07 · Grant · Acquired 10,900 · Balance 10,900 |
EXAGEN INC.
Report date June 09, 2023 · Filed June 13, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 · Expires 2033-06-08 | Direct | 9,000 |
Reported balance
After 2023-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-09 · Grant · Acquired 9,000 · Balance 9,000 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
OnKure Therapeutics, Inc.
Report date July 14, 2021 · Filed July 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 1
1 source rowRow 1 · 2021-07-14 · Sale · Disposed 111,736 · Balance 0 F1: The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2023 Filed Jun 13, 2023 16:35 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $3.13 | $0.00 |
DisclosureSEC source: 0001274737-23-000060 · wf-form4_168668852605535.xml · derivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 08:34 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0001274737-22-000046 · wf-form4_165581482752855.xml · derivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-15 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 08:25 UTC | EXAGEN INC. XGN · Entity 935 | PurchaseCommon Stock | 1,000 | $14.02 | $14,020.00 |
DisclosureSEC source: 0001274737-21-000101 · wf-form4_163101751499196.xml · nonDerivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 17:33 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | SaleCommon Stock | 111,736 | $8.50 | $949,756.00 |
DisclosureSEC source: 0001209191-21-046802 · doc4.xml · nonDerivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: The Reporting Person previously notified the Issuer of her intention to retire from her position as the Issuer's Chief Development Officer, effective on or before December 31, 2021. Following her announcement, the Reporting Person exercised an option totaling 111,736 shares of Common Stock of the Issuer (the "Shares") on July 8, 2021. The Reporting Person is selling the Shares privately to Abingworth Bioventures 8 LP ("Abingworth"), an existing stockholder of the Issuer. Bali Muralidhar, a Director of the Issuer, is a member of the investment committee of Abingworth. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 18:52 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | Exercise / conversionStock option (right to buy) · Derivative | 111,736 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001209191-21-046254 · doc4.xml · derivative · entry 2 Johnson Wendy S. · CIK 0001652822 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 111,736 shares Expires 2028-04-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2021 Filed Jul 9, 2021 18:52 UTC | OnKure Therapeutics, Inc. RPHM · Entity 6550 | Exercise / conversionCommon Stock | 111,736 | $1.97 | $220,119.92 |
DisclosureSEC source: 0001209191-21-046254 · doc4.xml · nonDerivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,736 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 08:38 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001274737-21-000074 · wf-form4_162427910066558.xml · derivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| October 01, 2020 Filed Oct 1, 2020 16:33 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 15,000 | $0.00 Strike: $11.25 | $0.00 |
DisclosureSEC source: 0001274737-20-000088 · wf-form4_160158439447223.xml · derivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The option is exercisable as it vests. The total number of shares of common stock subject to the option vests in 36 equal monthly installments over the three-year period beginning on November 1, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 07, 2017 Filed Sep 12, 2017 00:21 UTC | Armata Pharmaceuticals, Inc. APHB · Entity 6329 | GrantStock Option (Right to Buy) · Derivative | 10,900 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-17-052312 · doc4.xml · derivative · entry 1 Johnson Wendy S. · CIK 0001652822 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,900 Underlying: Common Stock · 10,900 shares Expires 2027-09-06 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.